#0146: Intranasal Delivery System for Treating Central Nervous System Disorders
………………………………………………………………………………………………………………
TECH FIELD(S)
Medical-Therapeutic
………………………………………………………………………………………………………………
FEATURES
Central nervous system disorders have a significant impact on the quality of life of millions of people worldwide. Therapeutic treatment of these disorders has been difficult to achieve due to the absence of a sustained drug delivery system, as oral and injected delivery of neuropeptides as therapeutic agents has been unsuccessful due to poor penetration of the drug to the desired location. To solve these problems, Indiana University School of Medicine researchers have developed a therapeutic approach that obviates the problems associated with systemic analog, liposome, and capsular neuropeptide delivery systems. This novel sustained release approach effectively delivers and provides a sustained release of neurologically active peptides to specific CNS loci for the treatment or prevention of known neurological disorders. This technology is related to Tech ID# 9625, a novel pharmacotherapeutic composition & process for treatment of central nervous system disorders, including a method for modulating glutamate and/or aspartate release in a central nervous system locus.
Fig 1: The rate of TRH release from P(FAD:SA) film.
………………………………………………………………………………………………………………
BENEFITS
- Minimally invasive intranasal delivery
- Time released delivery of therapeutic agents
………………………………………………………………………………………………………………
INVENTOR(S)
Michael J. Kubek, Ph.D.
Department of Anatomy and Cell Biology, Indiana University School of Medicine ………………………………………………………………………………………………………………
INTELLECTUAL PROPERTY STATUS
Issued Patent 7,229,635 B2
………………………………………………………………………………………………………………
CONTACT INFORMATION
For additional information on this technology, please contact Matt Rubin, Business Development Manager, IURTC:
Indiana University Research & Technology Corporation
351 West 10th Street
Indianapolis, IN 46202
Telephone: 317.278.1958
mrubin@iu.edu
………………………………………………………………………………………………………………
Still have a question? Ask here!